Investor relations

Bespoke solutions from clinical trial to launch

Investor relations

News

06/02/2012	Contracts with Materia Medica
16/01/2012	Holding(s) in Company
10/01/2012	Trading Update
22/12/2011	Placing
16/12/2011	Framework Agreement with TransGenRx Inc.
07/12/2011	UK Government Life Sciences Strategy
05/12/2011	Appointment of Commercial Director
17/10/2011	Intent to establish joint venture operation
23/09/2011	Change of Adviser
17/08/2011	Share Option Awards
25/07/2011	Appointment of WH Partnership re Cramlington
18/07/2011	Half Yearly Report
14/07/2011	Angel signs US consultancy agreement with BPTC
06/07/2011	Change of Accounting Reference Date
05/07/2011	Angel signs new contract with ReNeuron
05/07/2011	Contract with Angel Biotechnology Holdings plc
01/07/2011	Exercise of Options
14/06/2011	Angel's expertise assists Azellon
08/06/2011	Result of AGM
06/05/2011	Notice of AGM
04/05/2011	Angel signs contract with Pathfinder Cell Therapy
03/05/2011	Exercise of Employee Share Options
28/04/2011	Angel comments on ECJ opinion
18/04/2011	Postponement of AGM
12/04/2011	Exercise of Share Options
30/03/2011	Notice of AGM and posting of accounts
21/03/2011	Lease Agreement
16/03/2011	Appointment of Finance Director
28/02/2011	Final Results
11/02/2011	Re Agreement
02/02/2011	Additional Listing
27/01/2011	Placing
27/01/2011	Re Agreement
18/01/2011	Trading Update and Notice of Results
05/01/2011	Appointment of joint broker
23/12/2010	Angel to Further Produce ReN001 Stem Cells Batches
22/12/2010	New GMP Manufacturing Contract with Materia Medica
18/11/2010	Holding(s) in Company
16/11/2010	First Patient Treated with ReN001
09/11/2010	Business update
04/10/2010	New Materia Medica contract
16/09/2010	Issue of Shares
13/09/2010	Holdings in Company
04/08/2010	Share Option Awards
22/07/2010	Repayment of Loan
19/07/2010	Interim results for the 6 months to 30 June 2010
06/07/2010	Group Financial Controller & Company Secretary
03/06/2010	Trading Update
01/06/2010	New Materia Medica Contract
26/05/2010	Result of AGM
24/05/2010	Angel announces 3 contracts with Materia Medica
28/04/2010	Posting of Accounts and Notice of AGM
19/04/2010	New contract with Materia Medica
13/04/2010	Final Results
18/03/2010	Angel announces GMP contracts with ReNeuron
Last updated: 05:53 23/02/2012

Learn more

Contact us

for investor relations queries:
Gordon Sherriff
Chief Operating Officer
Tel:+44 (0)131 4456077
enquiries@angelbio.com

Our services

Along with the successful production of recombinants, Angel provides development and process scale-up strategies

Read more